sobetirome
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2008 (NCT00743405)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Thyroid hormone receptorINHIBITOR
Thyroid hormone receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(OCC(=O)O)cc(C)c1Cc1ccc(O)c(C(C)C)c1- Mol. weight
- 328.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL107400 ↗
Also known as
- (11c)gsk 1034702
- (3,5-dimethyl-4-(4'-hydoxy-3'-isopropylbenzyl)phenoxy)acetic acid
- gc-1
- gc-1
- gc-1
- gc 1 compound
- gc-1 compound
- gc-1 cpd
- gsk1034702
- gsk1034702
- gsk1034702
- gsk 1034702
- gsk-1034702
- gsk1043702
- qrx431
- qrx 431
- qrx-431
- qrx-431
- qrx-431
- sobetirome
- sobetirome
- sobetirome
- sobetirome
- sobetirome
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03196765 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2017 | NeuroVia, Inc. |
| NCT01787578 | Phase 1 | Apr 1, 2013 | Oregon Health and Science University |
| NCT00950586 | Phase 1 | Aug 1, 2009 | GlaxoSmithKline |
| NCT00937846 | Phase 1 | Jul 15, 2009 | GlaxoSmithKline |
| NCT00743405 | Phase 1 | May 1, 2008 | GlaxoSmithKline |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 1 | 2008 |
| NeuroVia, Inc. | For profit | 1 | 1 | 1 | 2017 |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1